05:08 PM EDT, 10/06/2025 (MT Newswires) -- KalVista Pharmaceuticals ( KALV ) said late Monday that the interim data from ongoing trials of Ekterly to treat hereditary angioedema attacks showed a halt in the progression of attacks and fast symptom relief with a median response time of 20 minutes.

The KONFIDENT-S trial data from 69 participants across 15 European countries showed that the treatment was well-tolerated, with a median time to symptom relief of 1.6 hours, the company said.

KalVista said it plans to launch the treatment in Germany this quarter, followed by more European launches in 2026. It presented the data at the 20th German Allergy Congress in Dusseldorf, Germany, between October 2 and 4.

Shares rose 1% during after-hours trading.